Skip to main content

Table 1 Adverse outcomes for sarcopenia versus non-sarcopenia

From: Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: a systematic review and meta-analysis

  N HR (95%CI) P I2, % P(Heterogeneity)
MACE overall 7 2.273 (1.581–3.268) < 0.001 60 0.02
Other 2 2.769 (1.630–4.706) < 0.001 67.5 0.079
PMI 3 2.861 (1.835–4.460) < 0.001 0 0.604
SMI/height squared 2 1.319 (0.570–3.050) 0.518 68.2 0.076
Prospective cohort 4 2.232 (1.278–3.898) 0.005 78.8 0.003
Retrospective cohort 3 2.315 (1.460–3.670) < 0.001 0 0.665
CAD 3 1.979 (0.984–3.983) 0.056 84.2 0.002
Non-STEMI 1 3.320 (1.727–6.381) < 0.001   
CABG 1 1.960 (0.827–4.644) 0.126   
Heart valve surgery 1 3.210 (1.374–7.501) 0.007   
STEMI 1 2.060 (1.011–4.196) 0.046   
Late mortality 3 2.152 (0.887–5.223) 0.09 91 < 0.001
Heart valve surgery 2 1.548 (0.7–3.422) 0.281 85.2 0.009
CABG 1 4.250 (2.181–8.283) < 0.001   
Death, HF-related hospitalization 2 1.370 (0.594–3.164) 0.459 62 0.105
All-cause mortality 2 1.354 (0.143–12.842) 0.792 90.5 0.001
  1. HR hazard ratio, CI confidence interval, MACE major adverse cardiovascular event, PMI psoas muscle area index, SMI skeletal muscle area index, CAD coronary artery disease, STEMI ST-elevated myocardial infarction, CABG coronary artery bypass graft, HF heart failure